Profusa Amends $1.87M Note to Convertible Equity with 19.99% Dilution Cap; Warrants Also Modified
PFSA sits 32% above its 52-week low of $0.41 on light trading volume (0.2× avg).
Summary
Profusa has modified its $1.87 million promissory note with NorthView Sponsor I, making it convertible into equity at the greater of 95% of the closing price or $0.35 per share, extending its maturity to December 31, 2026, and removing interest. A 19.99% exchange cap was added, requiring shareholder approval for further conversion. Additionally, a warrant with Ascent Partners Fund was amended to remove automatic conversion provisions in fundamental transactions. This follows the company's recent 8-K filing on April 24th regarding obtaining convertible debt and warrants, and an S-1 filing on April 28th for the resale of 179.3 million shares, indicating significant potential dilution. These amendments are critical for Profusa, a company with a very low market cap and a going concern warning, as they restructure existing debt to provide more flexibility and comply with Nasdaq rules regarding dilution. While the conversion feature introduces potential dilution for existing shareholders, the 19.99% cap offers some near-term protection by requiring shareholder approval for further conversion. Investors should monitor the upcoming shareholder vote for approval of further conversions and any subsequent filings related to the company's ongoing financing needs and capital structure.
At the time of this announcement, PFSA was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.41 to $975.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.